Year: 2026
Type: preprint
Abstract: The 2026 Bundibugyo virus (BDBV) disease outbreak in the Democratic Republic of the Congo (DRC) was declared a public health emergency (PHEIC) in May 2026 (1). Regional security concerns, debilitated medical infrastructure, diagnostic limitations, and lack of approved BDBV–specific medical countermeasures have contributed to rapid escalation of the outbreak (2). Currently, there are no licensed medical countermeasures for BDBV (3). Several BDBV-specific vaccines are in development (4), including a vesicular stomatitis virus (VSV)–based vaccine expressing the BDBV glycoprotein which has demonstrated strong preclinical efficacy (5-7); however, these candidates have not yet completed clinical evaluation. A licensed VSV-based vaccine expressing the Ebola virus glycoprotein (VSV-EBOV) (8) is available for human use and clinical (ERVEBO) and research grade (VSV-EBOV) material has been shown to elicit cross-reactive, cross-neutralizing and inconclusive cross-protective immune responses against the related BDBV (5,9-14). ERVEBO’s protective efficacy against BDBV, however, has not been formally established in the standard macaque model of BDBV infection. Macaques received a single human dose of ERVEBO or an unrelated VSV-based control vaccine and were challenged with BDBV 14 days after vaccination. ERVEBO vaccinated macaques exhibited significantly reduced clinical disease and strikingly increased survival, as well as significantly reduced viremia, mucosal viral shedding and disease-associated biochemistry markers consistent with protection against BDBV-mediated hepatorenal disease. These findings indicate that ERVEBO can rapidly mediate cross-protective immunity against BDBV.
Source: Research Square
Authors: Kyle Rosenke, Kyle O'Donnell, Paige Fletcher, Thomas Tipih, Amanda Griffin, Atsuhi Okumura, Shanna Brown, Samantha Ertl, Ekaterina Altynova, Vignesh Mariappan, Trenton Bushmaker, Anandhi Kannan, Akash Rajeev, Hannah Riel, Aaron B. Carmody, Brian Smith, Chad Clancy, Axel Lehrer, Andrea Marzi, Heinz Feldmann
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W7236830037
